Figure 3 | Scientific Reports

Figure 3

From: Transition from antigenemia to quantitative nucleic acid amplification testing in cytomegalovirus-seropositive kidney transplant recipients receiving preemptive therapy for cytomegalovirus infection

Figure 3

Primary and secondary outcomes: CMV-related events, CMV disease, acute rejection and graft function. (A) cumulative incidence of the first CMV-related event (infection or disease) according to the era. (B) cumulative incidence of CMV disease according to the era. (C) cumulative incidence of acute rejection according to the era. (D) graft function assessed by estimated glomerular filtration rate according to the era. In the figures (A–C), the P-value was calculated by log-rank. The means of graft function over time and according to era were compared by generalized estimating equation modeling and adjusted by Bonferroni test. Squares and circles in the plot represent mean and bars the 95% confidence interval. RT-PCR, real-time polymerase chain reaction].

Back to article page